CERo Therapeutics (NASDAQ:CERO) versus Atyr PHARMA (NASDAQ:ATYR) Head to Head Comparison

CERo Therapeutics (NASDAQ:CERO) and Atyr PHARMA (NASDAQ:ATYR) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, dividends, risk, earnings and valuation.

Risk & Volatility

CERo Therapeutics has a beta of 0.5, suggesting that its stock price is 50% less volatile than the S&P 500. Comparatively, Atyr PHARMA has a beta of 1.1, suggesting that its stock price is 10% more volatile than the S&P 500.

Profitability

This table compares CERo Therapeutics and Atyr PHARMA’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CERo Therapeutics	N/A	N/A	-108.43%
Atyr PHARMA	N/A	-79.44%	-59.16%

Institutional & Insider Ownership

29.6% of CERo Therapeutics shares are owned by institutional investors. Comparatively, 61.7% of Atyr PHARMA shares are owned by institutional investors. 18.0% of CERo Therapeutics shares are owned by company insiders. Comparatively, 3.7% of Atyr PHARMA shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation & Earnings

This table compares CERo Therapeutics and Atyr PHARMA”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CERo Therapeutics	N/A	N/A	-$2.54 million	N/A	N/A
Atyr PHARMA	$350,000.00	856.19	-$50.39 million	($0.94)	-3.80

CERo Therapeutics has higher earnings, but lower revenue than Atyr PHARMA.

Analyst Ratings

This is a summary of recent recommendations and price targets for CERo Therapeutics and Atyr PHARMA, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CERo Therapeutics	0	0	0	0	0.00
Atyr PHARMA	0	0	5	0	3.00

Atyr PHARMA has a consensus target price of $19.25, suggesting a potential upside of 439.22%. Given Atyr PHARMA’s stronger consensus rating and higher possible upside, analysts clearly believe Atyr PHARMA is more favorable than CERo Therapeutics.

Summary

Atyr PHARMA beats CERo Therapeutics on 7 of the 10 factors compared between the two stocks.

About CERo Therapeutics

CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.

About Atyr PHARMA

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.